{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-032347","form_type":"8-K","ticker":"BBLG","cik":"0001419554","company_name":"Bone Biologics Corp","filed_at":"2023-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.870886+00:00","generated_at":"2026-06-10T20:43:42.930103+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Bone Biologics stockholders elect directors and approve all proposals at annual meeting","bullets":["Four director nominees elected: Hankey, Stroever, Lucera, Angle; broker non-votes of 578,270 for each.","Advisory vote on executive compensation approved: 904,764 for, 84,094 against, 307,376 abstentions.","Advisory frequency vote selects every year (958,400 votes); board adopts annual say-on-pay policy.","Ratification of Weinberg & Company as auditor for FY2023: 1,513,051 for, 61,316 against.","First Amendment to 2015 Equity Incentive Plan approved: 863,931 for, 123,150 against, 309,153 abstentions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-032347","json":"https://secwatch.observer/filing/0001493152-23-032347.json","markdown":"https://secwatch.observer/filing/0001493152-23-032347.md","text":"https://secwatch.observer/filing/0001493152-23-032347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223032347/0001493152-23-032347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223032347/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T20:43:42.930103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b0a03fee034389d6d354b0242410cc182eb8270","claim":"Bone Biologics Corp shareholders approved Ratification of Weinberg & Company, P.A. as independent auditor at the 2023-09-12 meeting.","evidence_excerpt":"The Company’s stockholders ratified the appointment of Weinberg & Company, P.A. as the Company’s independent registered public accounting firm","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223032347/0001493152-23-032347-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-12"}],"fact_type":"shareholder_vote"},{"claim_id":"548a82fb298b1e000d4e9f3b4e205dda75e3df05","claim":"Bone Biologics Corp shareholders approved Advisory vote on executive compensation at the 2023-09-12 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, the Company’s executive compensation.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223032347/0001493152-23-032347-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-12"}],"fact_type":"shareholder_vote"},{"claim_id":"7f999c7eccd213e59437c044c9c5668dfaf8f4dc","claim":"Bone Biologics Corp shareholders approved Frequency of future say-on-pay votes at the 2023-09-12 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, that future say-on-pay votes should occur every year.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223032347/0001493152-23-032347-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-12"}],"fact_type":"shareholder_vote"},{"claim_id":"c047f670959d2f5dffb9c72d2c4f098ff9ecb4b0","claim":"Bone Biologics Corp shareholders approved Approval of First Amendment to 2015 Equity Incentive Plan at the 2023-09-12 meeting.","evidence_excerpt":"The Company’s stockholders approved the First Amendment to the Company’s 2015 Equity Incentive Plan.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223032347/0001493152-23-032347-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-12"}],"fact_type":"shareholder_vote"},{"claim_id":"edc61663b48026f8456ac2e156a027bc3cbcb4ff","claim":"Bone Biologics Corp shareholders approved Election of directors at the 2023-09-12 meeting.","evidence_excerpt":"The Company’s stockholders elected the following four director nominees to serve until the date of the next Annual Meeting","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223032347/0001493152-23-032347-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-12"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}